FOI 26-3145 IR – Procurement and use of Fivecast software

Written by Claude Haiku 5.5 from the extracted text on 16 Oct 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

This FOI release (FOI 26-3145 IR) concerns the Therapeutic Goods Administration's procurement and use of Fivecast software, an open-source intelligence (OSINT) platform. The core document is a Commitment Approval Minute recommending approval of $107,250.00 (GST inclusive) to purchase three Fivecast Onyx Pro licences for 12 months, with a Section 60 PGPA Act indemnity assessed as medium risk. The purchase is justified on the basis that the Regulatory Compliance Branch's intelligence team needs tools to handle growing intelligence referrals. Limited tender was used under CPR 10.3.d because the software is proprietary. Related email chains, option analyses, and a comparison with OSINTCombine's Nexus Xplore are also included. Each tool was estimated at $130,000 to $250,000 a year. The release also contains ICT Acceptable Use and Integrity policies. No clinical, PBS or TGA product-evaluation data appear in the excerpt.